(C) 2012 Elsevier B.V. All rights reserved.”
“The clustering of risk factors including dyslipidemia, hyperglycemia, and hypertension is highly atherogenic along with the excess of remnants from triglyceride (TG)-rich lipoproteins. CD36 is involved in the uptake of long-chain fatty learn more acids (LCFAs) in muscles and small intestines. Patients with CD36 deficiency (CD36-D) have postprandial hypertriglyceridemia, insulin resistance, and hypertension. To investigate the underlying mechanism of postprandial hypertriglyceridemia in CD36-D, we analyzed lipoprotein profiles of CD36-D patients and CD36-knockout (CD36-KO) mice after oral fat loading (OFL). In CD36-D patients, plasma triglycerides,

apolipoprotein B-48 (apoB-48), free fatty acids (FFAs), and free glycerol levels were much higher after OFL than those of controls, along with increases in chylomicron (CM) remnants and small dense low-density lipoprotein (sdLDL) particles. In CD36-KO mice, lipoproteins smaller than CM in size in plasma and intestinal lymph were markedly increased after OFL and mRNA levels of genes involved in FFA biosynthesis, such as fatty acid binding protein (FABP)-1 and FAS, were significantly increased. jlr These results suggest that CD36-D

might increase atherosclerotic risk by enhancing plasma level of CM remnants due to the increased synthesis of lipoproteins smaller than CM in size in the intestine.-Masuda, D., K. Hirano, H. Oku, J. C. Sandoval, R. Kawase, M. Belinostat Yuasa-Kawase, Y. Yamashita, M. Takada, K. Tsubakio-Yamamoto, Y. Tochino, M. Koseki, CAL-101 cost F. Matsuura, M. Nishida, T. Kawamoto, M. Ishigami, M. Hori, I. Shimomura, and S. Yamashita. Chylomicron remnants are increased in the postprandial state in CD36 deficiency. J. Lipid Res. 2009. 50: 999-1011.”
“Background Some studies suggest that patients with asthma who are homozygous for arginine at the 16th aminoacid position of the beta(2)-adrenergic receptor (B16 Arg/Arg) benefit less from

treatment with longacting beta(2) agonists and inhaled corticosteroids than do those homozygous for glycine (B16 Gly/Gly). We investigated whether there is a genotype-specific response to treatment with a longacting beta(2) agonist in combination with inhaled corticosteroid.\n\nMethods In this multicentre, randomised, double-blind, placebo-controlled trial, adult patients with moderate asthma were enrolled in pairs matched for forced expiratory volume in 1 s and ethnic origin, according to whether they had the B16 Arg/Arg (n=42) or B16 Gly/Gly (n=45) genotype. Individuals in a matched pair were randomly assigned by computer-generated randomisation sequence to receive inhaled longacting beta(2) agonist (salmeterol 50 mu g twice a day) or placebo given in a double-blind, crossover design for two 18-week periods.